# US 2024/0197757 A1 · Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197757 A1
- Document ID: US20240197757A1
- Status: Published application
- Kind: A1
- Application number: 18/457,738
- Filed: 2023-08-29
- Published: 2024-06-20
- Earliest claimed: 2009-06-08
- Assignees: AbbVie Deutschland GmbH & Co. KG
- Applicants: AbbVie Deutschland GmbH & Co. KG
- Inventors: Claudia Henzel; Norbert Steiger; Bernd Liepold; Drazen Kostelac; Martin Knobloch
- Web page: https://patentgrep.com/patent/US20240197757A1

## CPC

- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2095: {Tabletting processes}
- A61K 9/4833: {Encapsulating processes; Filling of capsules (mechanical aspects A61J3/07)}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a pharmaceutical dosage form which comprises a solid dispersion product comprising N—(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl) propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or a salt, hydrate or solvate thereof, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer. The invention is further directed to processes for preparing the pharmaceutical dosage form and to use of the dosage form for treating proliferative disorders.

## Claims

### Claim 1

A pharmaceutical composition comprising (a)N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl) methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide, a pharmaceutically acceptable salt, hydrate, or solvate thereof and (b) a JAK2 inhibitor, a pharmaceutically acceptable salt, hydrate, or solvate thereof.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1 further comprising a pharmaceutically acceptable excipient.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1 wherein the JAK2 inhibitor is selected from the group consistent of CEP-701 (lesaurtinib), XL019, INCB-018424, and any combination thereof.

### Claim 4

A pharmaceutical dosage form comprising:
N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide, a salt, a hydrate, or a solvate thereof;
at least one pharmaceutically acceptable polymer comprising a copolymer of N-vinyl pyrrolidone;
a single pharmaceutically acceptable solubilizer, said single pharmaceutically acceptable solubilizer being a tocopheryl compound having a polyalkylene glycol moiety;
wherein the N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide, a salt, a hydrate, or a solvate thereof is dispersed within a solid dispersion product in a concentration from 0.5 to 40% by weight, the solid dispersion product further comprising from 40 to 97.5% by weight of the at least one pharmaceutically acceptable polymer and from 2 to 20% by weight of the single pharmaceutically acceptable solubilizer.

### Claim 5 (depends on 4)

A method for treating a proliferative disorder, comprising administering the dosage form of claim 4 to a subject in need thereof.

### Claim 6 (depends on 4)

A process for preparing a solid dosage form of claim 4, comprising: (a) preparing a homogeneous melt of the pharmaceutically active ingredient or a salt, hydrate or solvate thereof, the at least one pharmaceutically acceptable polymer and the at least one solubilizer, and (b) allowing the melt to solidify to obtain a solid dispersion product.

### Claim 7

A pharmaceutical product comprising (a) a first pharmaceutical composition comprising N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl) methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide, a pharmaceutically acceptable salt, hydrate, or solvate thereof, and (b) a second pharmaceutical composition comprising a JAK2 inhibitor, a pharmaceutically acceptable salt, hydrate, or solvate thereof.

### Claim 8 (depends on 7)

The pharmaceutical product of claim 7 wherein the first pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

### Claim 9 (depends on 7)

The pharmaceutical product of claim 7 wherein the second pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

### Claim 10 (depends on 7)

The pharmaceutical product of claim 7 wherein the first pharmaceutical composition and the second pharmaceutical composition are the same.

### Claim 11 (depends on 7)

The pharmaceutical product of claim 7 wherein the JAK2 inhibitor is selected from the group consistent of CEP-701 (lesaurtinib), XL019, INCB-018424, and any combination thereof.

### Claim at position 12

12-21. (canceled)
